Paolo Vigneri

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

J. Radich, H. Kantarjian, D. B. Yehuda, 2013, Blood.

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Francisco Cervantes, Ryuzo Ohno, Richard E. Clark, 2013, Blood.

Nuclear entrapment of BCR–ABL by combining imatinib mesylate with leptomycin B does not eliminate CD34+ chronic myeloid leukaemia cells

A. Hamilton, P. Vigneri, T. Holyoake, 2009, Leukemia.